-
Loading metrics
Open Access
Peer-reviewed
Research Article
The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats
-
Derek M. Erion ,
* E-mail: derek.erion@pfizer.com
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Amanda Lapworth,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Paul A. Amor,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Guoyun Bai,
Affiliation Groton Center of Chemistry, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
⨯ -
Nicholas B. Vera,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Ronald W. Clark,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Qingyun Yan,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Yimin Zhu,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Trenton T. Ross,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Julie Purkal,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Matthew Gorgoglione,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Guodong Zhang,
Affiliation Groton Center of Chemistry, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
⨯ -
Vinicius Bonato,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Levenia Baker,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Nicole Barucci,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Theresa D’Aquila,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Alan Robertson,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Robert J. Aiello,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Jiangli Yan,
Affiliation Groton Center of Chemistry, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
⨯ -
Jeff Trimmer,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ -
Timothy P. Rolph,
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ - [ ... ],
-
Jeffrey A. Pfefferkorn
Affiliation Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America
⨯ - [ view all ]
- [ view less ]
The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats
- Derek M. Erion,
- Amanda Lapworth,
- Paul A. Amor,
- Guoyun Bai,
- Nicholas B. Vera,
- Ronald W. Clark,
- Qingyun Yan,
- Yimin Zhu,
- Trenton T. Ross,
- Julie Purkal
- Published: May 23, 2014
- https://doi.org/10.1371/journal.pone.0097139